Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hormonal refractory, chemotherapy, docetaxel, gemcitabine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

docetaxel

Intervention Type DRUG

gemcitabine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically verified adenocarcinoma of the prostate.
* Hormone refractory prostate cancer (HRPC) defined as progression during previous anti-hormone treatment. Patients must have been off previous anti-androgen therapy for more than 4 weeks.
* Stage IV disease (verified by imaging or clinical examination).
* PSA \> 10 microgram/l.
* PSA progression defined as a \> 25% increase between two independent measurements performed with a 1-month interval or more after discontinuation of anti-androgen treatment.
* Castrate level of testosterone (\< 50 ng).
* No previous oestrogen or steroid as metastatic prostate cancer treatment.
* Satisfactory hepatic function in the form of total bilirubin ≤ UNL (upper normal limit), ASAT/ALAT ≤ 2.5 x UNL, alkaline phosphatase ≤ 5 x UNL.
* Satisfactory renal function, defined as serum creatinine ≤ 1.5 x UNL.
* Satisfactory haematologic function defined as ANC \>1.5 x 10\^9/l, leucocytes \>3.0 x 10\^9/l, thrombocytes ≥ 100 x 10\^9/l, haemoglobin \> 7 mmol/l
* ECOG performance status ≤ 2.
* Life expectancy \> 3 months.
* Patient must be able to adhere to protocol requirements.
* Written informed consent.
* \> 18 years of age.

Exclusion Criteria

* Previous prostate cancer treatment with oestrogens or steroid hormones.
* Previous chemotherapy.
* Previous treatment with systemic radioactive isotopes.
* Bisphosphonate treatment (concomitant).
* Radiation therapy covering more than 25% of the bone marrow producing area.
* Other serious coincidental and/or concomitant medical condition.
* Symptomatic cerebral metastases.
* Other previous or current malignant disease, excluding \*adequately treated and cured planocellular skin carcinoma; or \*other cancer assessed to carry minimal risk of recurrence.
* ECOG performance status \> 2.

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lisa Sengelov, MD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Oncology, Herlev Hospital, 2730 Herlev, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Oncology, 54B1, Herlev Hospital

Herlev, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EudraCT number: 2004-002353-31

Identifier Type: -

Identifier Source: secondary_id

UR0416